GlobeNewswire

PRESS RELEASE: NACON IS PUBLISHING THE GAME WAR HOSPITAL DEVELOPED BY BRAVE LAMB STUDIO

Share

NACONIS PUBLISHING THE GAME WAR HOSPITAL
DEVELOPED BY BRAVE LAMB STUDIO

Lesquin, 26 August 2021NACON and Brave Lamb Studio are pleased to announce that they have joined forces for the publication of the game War Hospital, a unique strategy and survival game in which the player controls the fate of a British field hospital during the Great War.

In War Hospital players are confronted by the human drama resulting from the terrible conflict that has so deeply marked our recent history. Every day, when barbarity is unleashed, the hospital doctors have to deal with the moral dilemmas associated with the dual nature of their task, which is both humanitarian and military. They fight not only for life, but also to maintain their morale and humanity in a world that seems to have rejected them completely.

In the very creative strategy and survival game segment, War Hospital provides a unique experience that blends real-time strategy, survival and RPG elements, while developing a theme rarely dealt with until now. The game is set in 1917. You play as Major Henry Wells, a British doctor sent to the front to treat the wounded in an attempt to give a glimmer of hope to the troops.

Despite the difficult conditions and the lack of equipment and resources, you must manage how emergencies are handled and develop your hospital. Thanks to the exceptional support that the British Imperial War Museums gave the developers, the game faithfully recreates the context of the front and its trenches, as well as the medical equipment available at the time.

In addition to the deep management gameplay, the game also requires players to make moral choices that affect the soldiers, the situation at the front and the battles. The player therefore undergoes an emotional trial through the drama experienced by the soldiers sent into the carnage. The game broaches the subject of war very differently than is usually the case.

"We are excited to partner with Nacon. We believe that this will help to introduce War Hospital to more players around the world and show them a different face of war in video games." stated Michał Dziwniel, Head of Studio.

Nacon is especially proud and honoured to have been selected by Brave Lambs to work together on the success of War Hospital, a unique game in the genre, once again demonstrating, on the heels of titles such as This War of Mine and Soldats Inconnus that our media can deal with subjects that are complex and serious while keeping their identity,” stated Benoît Clerc, Publishing Director at NACON.

More information about War Hospital will be provided at a later date.

Steam page
https://store.steampowered.com/app/1553000/War_Hospital/

-------

About NACON

NACON is a company of the BIGBEN Group founded in 2019 to optimize its know-how through strong synergies in the video game market. By bringing together its 12 development studios, the publishing of AA video games, the design and distribution of premium gaming devices, NACON focuses 20 years of expertise at the service of players. This new unified business unit strengthens NACON's position in the market and enables it to innovate by creating new unique competitive advantages. https://corporate.nacongaming.com/

About Brave Lamb Studio

Brave Lamb Studio is an independent studio located in Poland, Warsaw. The studio currently has 17 employees consisting of former Techland, CD Projekt Red, People Can Fly, and Fuero Games specialists, and is focused on games in which the player has to make emotion-based choices, analysing specific problems from different perspectives. The studio was established in 2020, after one year of informal War Hospital pre-production. Brave Lamb Studio is led by Michael Dziwniel – an industry veteran with 13 years of experience.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer19.9.2021 13:30:00 CEST | Press release

With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting2 Kisqali plus letrozole achieved median OS of over five years (63.9 months), a survival benefit of over 12 months vs. placebo plus letrozole in postmenopausal women (HR=0.76; p=0.004)2 Kisqali is the only CDK4/6 inhibitor with proven OS benefit across all three Phase III trials of the MONALEESA program with different endocrine therapy partners, regardless of menopausal status or line of therapy2-4 MONALEESA-2 OS data to be presented at ESMO Congress 2021 as a late-breaker in an oral session The digital press release with multimedia content can be accessed here: Basel, September 19, 2021 — Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combinati

Hypefactors announces launch of 4th generation Reputation AI18.9.2021 10:37:51 CEST | Press release

Copenhagen, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Announcement no. 13-2021 Inside Information Copenhagen, 18. September 2021 The SaaS company Hypefactors, that delivers a unified solution for media intelligence and reputation tracking, will launch its next generation Reputation AI (artificial intelligence) on September 20, 2021. Through algorithmic advances in machine learning, as well as drastically increased data curated by a team of in-house recruited linguists with diverse language and cultural backgrounds, Hypefactors incorporates the latest scientific advances in natural language processing to deliver unprecedented accuracy, precision and automation to commercial end-users. AI-assisted reputation tracking is a core feature of Hypefactors and enables large scale tracking from social media, news websites, tv, radio and reviews across the world. These real-time reputation insights can reveal early-stage opportunities (e.g. GameStop media hype), and/or defensively as an on-going protect

Repurchase of shares in Millicom17.9.2021 23:00:00 CEST | Press release

Repurchase of shares in Millicom Luxembourg, September17, 2021 - During the period September 9, 2021 – September 15, 2021, Millicom repurchased a total of 131,559 of its Swedish Depository Receipts (SDRs), hereinafter referred to as shares within the framework of the repurchase program announced on July 29, 2021, details of which are shown in the table below. DateNumber of shares repurchasedWeighted average repurchaseprice (SEK) excluding commissionsTotal daily transaction value (SEK), excluding commissions 09/09/2021 15,000 322.6863 4,840,294.50 10/09/2021 30,000 322.1097 9,663,291.00 13/09/2021 17,974 322.3942 5,794,713.35 14/09/2021 15,725 321.5394 5,056,207.07 15/09/2021 52,860 314.4509 16,621,874.57 All purchases were carried out on Nasdaq Stockholm by Citigroup Global Markets Limited on behalf of Millicom. Following the purchases, as of September 15, 2021, Millicom holds 792,425 treasury shares. The total number of shares outstanding in Millicom is 101,739,217. The repurchase pro

Palette Life Sciences lanserar ny varumärkeswebbplats med USA:s portfölj17.9.2021 18:09:14 CEST | Pressemelding

Varumärkesuppdatering för USA och globala kommersiella produkter för behandling av ouppfyllda medicinska behov SANTA BARBARA, Kalifornien och STOCKHOLM, Sverige, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett helt integrerat globalt företag inom biovetenskap som arbetar för att förbättra patientutfall, lanserade idag sin nyligen uppdaterade webbplats Palettelifesciences.com. Webbplatsen har ett uppdaterat företagsvarumärke som stöder alla produkter i Palette Life Sciences-portföljen, och som fokuserar på minimalt invasiva behandlingar inriktade på ouppfyllda medicinska behov vid strålbehandling och interventionella onkologiska ingrepp, urologiska/urogynekologiska sjukdomar och kolorektala tillstånd. ”Vi inom Palette är stolta över vår förstklassiga produktportfölj som ger hopp åt dem med ouppfyllda medicinska behov”, säger Per G. Langö, Chief Executive Officer och Board Director för Palette Life Sciences. ”När vi bytte varumärke på vår webbplats övervägde vi hur vi bäst

Prosafe SE: bp charters Safe Zephyrus in 202217.9.2021 17:40:15 CEST | Press release

BP Exploration Operating Company Limited ('bp') has chartered the Safe Zephyrus to provide gangway connected operations to support the Seagull project at the ETAP central processing facility in the UK North Sea. The firm duration of the contract, starting Q1 2022, is 10 months with up to four months of options. The Safe Zephyrus is one of the world's most advanced and versatile accommodation vessels, complying with stringent rules in both UK and Norway and with a strong focus on reducing emissions by optimising the engine load. The value of the contract firm duration is USD 35.5 million, and the firm duration including options value is USD 49.3 million. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com 17 September 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.9.2021 16:20:00 CEST | Press release

Bid procedure, 2021-09-23BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 520, SE0014694659, 2027-09-15 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2021-09-23Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 400 mln SEK +/-200 mln SEK 1591: 1900 mln SEK +/-950 mln SEK 146: 700 mln SEK +/-350 mln SEK 581: 500 mln SEK +/-250 mln SEK 520: 600 mln SEK +/-300 mln SEK 2312: 500 mln SEK +/-250 mln SEK 5536: 400 mln SEK +/-200 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 400 mln SEK per bid 1591: 1900 mln SEK per bid 146: 700 mln SEK per bid 581: 500 mln SEK per bid 520: 600 mln SEK per bid 2312: 500 mln SEK per bid 5536: 400 mln SEK per bid Lowest permitted bid volume (co

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 16:20:00 CEST | Press release

Bid procedure, 2021-09-24BondsSWEDISH GOVERNMENT: 1056. SE0004517290. 2032-06-01 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2021-09-24Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1056: 500 mln SEK +/-250 mln SEK 1053: 750 mln SEK +/-350 mln SEK Highest permitted bid volume (corresponding nominal amount)1056: 500 mln SEK per bid 1053: 750 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-09-28Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-09-17 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c